Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1

1. A compound of formula I

wherein D is CH;

E is N;

G is CH;

J is CH;

R 1 is

hydrogen or halogen;

R 2 is NR 5 R 6 ;

R 3 is

(a) hydrogen;

(b) C 1-6 alkyl, which is optionally substituted with halo, hydroxyl, amino, phenyl, heterocyclyl, C 1-6 alkyl or R 10 ;

(c) C 2-6 alkenyl, which is optionally substituted with halo, hydroxyl, amino, phenyl, heterocyclyl or C 1-6 alkyl;

(d) C 2-6 alkynyl, which is optionally substituted with one or two substituents independently selected from halo, hydroxyl, amino, phenyl (which is optionally substituted with C 1-6 alkyl), heterocyclyl, heteroaryl, C 1-6 alkyl or Si(CH 3 ) 3 ;

(e) C 3-10 cycloalkyl, which is optionally substituted with C 1-6 alkyl, —OR 13 , —NR 13 R 14 , phenyl (which is optionally substituted with C 1-6 alkyl, —OR 13 or —NR 13 R 14 ), halo, R 10 or heterocyclyl;

(f) —(C═O)R 11 ;

(g) —(C═O)NR 9 R 13 ;

(h) —(C═O)NHNH(C═O)R 11 ;

(i) C 4-10 heterocyclyl, which is optionally substituted on either the carbon or the heteroatom with C 1-6 alkyl, halo, R 10 , —OR 13 , —NR 13 R 14 , phenyl (which is optionally substituted with C 1-6 alkyl, OR 13 or NR 13 R 14 ), —(C═O)R 9 or —(C═O)NR 13 R 14 ;

(j) —OR 13 ;

(k) —NH(C═O)R 11 ;

(l) halo;

(m) Aryl, which is optionally substituted with one to three groups independently selected from C 1-6 alkyl (which is optionally substituted with one to three halo, cyano or heterocyclyl), halo, heterocyclyl, or R 10 ;

(n) Heteroaryl, which is optionally substituted on either the carbon or the heteroatom with one to three groups independently selected from C 1-6 alkyl (which is optionally substituted with one to three halo or hydroxy), halo, heterocyclyl, R 10 or R 11 ;

(o) —O(aryl), which is optionally substituted with one to three groups independently selected from C 1-6 alkyl, halo or R 10 ;

(p) —O(C 1-6 alkyl), which is optionally substituted with one to three groups independently selected from C 1-6 alkyl, halo or R 10 ;

(q) —SO m (C 1-6 alkyl); or

(r) —SO m (aryl);

R 4 is

(a) hydrogen;

(b) C 1-6 alkyl, which is optionally substituted with halo, hydroxyl, amino, aryl or heterocyclyl;

R 5 is

(a) C 1-6 alkyl, which is optionally substituted with one to three substituents independently selected from halo, cyano, C 1-6 alkyl, C 3-10 cycloalkyl, C 1-6 haloalkyl, aryl, —NR 13 R 14 , Si(CH 3 ) 3 , SO m (C 1-6 alkyl), —(C═O)OR 13 , OR 13 or hydroxyl;

(b) C 3-10 cycloalkyl, which is optionally substituted with one to three substitutents independently selected from halo, aryl, (C 1-6 alkyl)OH or C 1-6 alkyl;

(c) aryl, which is optionally substituted with one to three substituents independently selected from halo, C 1-6 alkyl, aryl, hydroxyl, O(heteroaryl), C 1-6 haloalkyl or heteroaryl;

(d) heteroaryl;

(e) (C 1-6 alkyl)(aryl), which is optionally substituted on the alkyl and aryl groups with one to three substituents independently selected from halo, cyano, C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl or O(C 1-6 alkyl);

(f) (C 1-6 alkyl)(heteroaryl), which is optionally substituted on the alkyl and heteroaryl groups with one to three substituents independently selected from halo, C 1-6 haloalkyl or C 1-6 alkyl;

(g) (C 1-6 alkyl)(heterocyclyl);

(h) heterocyclyl, which is optionally substituted with one to four substituents independently selected from halo, R 7 , (C 1-6 alkyl)R 7 , (C═O)R 7 , (C═O)OR 7 , (C═O)NHR 7 , (SO m )R 9

(i) C 1-6 alkyl)(C 3-10 cycloalkyl) which is optionally substituted on the alkyl with aryl;

(j) C 1-6 alkyl(C═O)OH;

R 6 is

hydrogen;

R 7 is

(a) hydrogen;

(b) C 1-6 alkyl, which is optionally substituted with halo, cyano, hydroxyl, amino, aryl (which is optionally substituted with halo, C 1-6 alkyl, O(C 1-6 alkyl) or NR 8 R 9 ), heterocyclyl, C 3-10 cycloalkyl, C 1-6 haloalkyl, NH(C═O)R 13 , SO m NR 13 R 14 or NR 13 R 14 ;

(c) C 3-10 cycloalkyl, which is optionally substituted with one to three substituents independently selected from halo, hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, —OR 4 , —NR 8 R 4 or phenyl (which is optionally substituted with C 1-6 alkyl, —OR 4 , —NR 8 R 4 , heterocyclyl, —(CO)R 8 or —(CO)NR 8 R 9 );

(d) C 4-10 heterocyclyl which is optionally substituted on either the carbon or the heteroatom with one to three substituents independently selected from halo, C 1-6 alkyl, —OR 13 , —NR 13 R 14 , phenyl (which is optionally substituted with C 1-6 alkyl, —OR 13 , —NR 13 R 14 , heterocyclyl, —(CO)R 9 or —(CO)—NR 13 R 14 );

(e) Aryl, which is optionally substituted with one to three substituents independently selected from halo, NR 13 R 14 or C 1-6 haloalkyl;

(f) Heteroaryl, which is optionally substituted on either the carbon or heteroatom with NR 13 R 14 ;

R 8 is hydrogen, C 1-6 alkyl, (C 1-6 alkyl)aryl, (C 1-6 alkenyl)aryl, (C 1-6 alkyl)OR 9 , —OR 13 , —NR 13 R 14 , —(CO)NR 13 R 14 , heterocyclyl or phenyl (which is optionally substituted with C 1-6 alkyl, —OR 13 , —NR 13 R 14 , heterocyclyl, —(CO)R 9 or —(CO)—NR 13 R 14 );

R 9 is hydrogen, C 1-6 alkyl, (C 1-6 alkyl)aryl, (C 1-6 alkyl)heterocyclyl, heteroaryl, heterocyclyl, C 3-6 cycloalkyl or —NR 13 NR 14 ;

R 10 is:

(a) hydrogen;

(b) —OR 11 ;

(c) —O(C 1-6 haloalkyl);

(b) —CO 2 R 11 ;

(c) —(C═O)R 11 ;

(d) —NHR 11 ;

(e) —NR 11 R 12 ;

(f) —NHS(O) 2 R 11 ;

(g) —NH(C═O)R 11 ;

(h) —NH(C═O)OR 11 ;

(i) —NH—C═(NH)NH 2 ;

(j) —NH(C═O)NH 2 ;

(k) —NH(C═O)NHR 11 ;

(l) —NH(C═O)NR 11 R 12 ;

(m) —NHC 3-6 cycloalkyl;

(n) —(C═O)NHR 11 ;

(o)—(C═O)NR 11 R 12 ;

(p) —SO 2 NHR 11 ;

(q) —SO 2 NH(C═O)R 12 ; or

(r) —SO 2 R 11 ;

(s) heterocyclyl;

R 11 is selected from the group consisting of:

(a) hydrogen,

(b) C 3-6 cycloalkyl, which is optionally substituted with aryl, heteroaryl or one to five halo;

(c) C 1-6 alkyl, which is optionally substituted with aryl, heteroaryl, heterocyclyl, cyano, NR 13 R 14 , OR 13 or one to five halo;

(d) Aryl, which is optionally substituted with one to five halo;

(e) Heteroaryl (wherein the heteroaryl has 5 or 6 members in which 1, 2, 3 or 4 of the atoms is a heteroatom selected from N, S and O), which is optionally substituted on either the carbon or the heteroatom with one to five halo;

(f) Heterocyclyl, which is optionally substituted with (C 1-6 alkyl)OH;

R 12 is selected from the group consisting of:

(a) hydrogen,

(b) C 1-6 alkyl, which is optionally substituted with aryl, heteroaryl or one to five halo;

(c) C 3-6 cycloalkyl, which is optionally substituted with aryl, heteroaryl or one to five halo;

(d) Aryl, which is optionally substituted with one to five halo;

(e) Heteroaryl (wherein the heteroaryl has 5 or 6 members in which 1, 2 3 or 4 of the atoms is a heteroatom selected from N, S and O), which is optionally substituted on either the carbon or the heteroatom with one to five halo;

R 13 is hydrogen or C 1-6 alkyl;

R 14 is hydrogen or C 1-6 alkyl;

A is

hydrogen;

(o)

m is 0, 1 or 2;

n is 0;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound of claim 1 wherein R 5 is

(a) C 1-6 alkyl, which is optionally substituted with one to three substituents independently selected from halo, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 haloalkyl, aryl, —NR 13 R 14 or hydroxyl; or

(b) aryl, which is optionally substituted with one to three substituents independently selected from halo, C 1-6 alkyl, aryl, hydroxyl, —O(heteroaryl) or heteroaryl;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. The compound of claim 2 wherein R 5 is C 1-6 alkyl, which is substituted with one to three substituents independently selected from halo or C 1-6 haloalkyl; or a pharmaceutically acceptable salt or stereoisomer thereof.

4. The compound of claim 3 wherein R 5 is C 1-6 alkyl, which is substituted with trifluoromethyl; or a pharmaceutically acceptable salt or stereoisomer thereof.

5. A compound which is

6-{[(1R)-2-methyl-1-(trifluoromethyl)propyl]amino}pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

6-{[1-(2,4-dichloro-5-fluorophenyl)ethyl]amino}pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

6-[(2,2,2-trifluoroethyl)amino]pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

6-[(3-thienylmethyl)amino]pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

6-[(1,3-thiazol-2-ylmethyl)amino]pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

6-[(pyridin-2-ylmethyl)amino]pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

6-{[(5-methylisoxazol-3-yl)methyl]amino}pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

tert-butyl (3S)-3-[(1-oxo-1,2-dihydropyrido[4,3-c]-1,6-naphthyridin-6-yl)amino]piperidine-1-carboxylate;

6-(benzylamino)pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

6-(methylamino)pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

6-(dimethylamino)pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

6-(benzylamino)pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

6-{[(1R)-1,2,2-trimethylpropyl]amino}pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

6-{[(1S)-1,2,2-trimethylpropyl]amino}pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

4-iodo-6-[(1,2,2-trimethylpropyl)amino]pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

4-iodo-6-[(1,3-thiazol-2-ylmethyl)amino]pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

4-iodo-6-[(2,2,2-trifluoroethyl)amino]pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

4-iodo-6-{[(5-methylisoxazol-3-yl)methyl]amino}pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

tert-butyl (3S)-3-[(4-iodo-1-oxo-1,2-dihydropyrido[4,3-c]-1,6-naphthyridin-6-yl)amino]piperidine-1-carboxylate;

4-iodo-6-[(pyridin-2-ylmethyl)amino]pyrido[4,3-c]-1,6-naphthyridin-1(2H)-one;

or a pharmaceutically acceptable salt or stereoisomer thereof.

6. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to claim 1 , and a pharmaceutically acceptable carrier.

7. A method of treating a myeloproliferative disorder in a mammal in need thereof with a therapeutically effective amount of a compound of claim 1 , wherein the myeloproliferative disorder is selected from polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM), chronic myelogenous leukemia (CML), myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), juvenile myelomonocytic leukemia (JMML), or systemic mast cell disease (SMCD).

8. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to claim 5 , and a pharmaceutically acceptable carrier.

9. A method of treating a myeloproliferative disorder in a mammal in need thereof with a therapeutically effective amount of a compound of claim 5 , wherein the myeloproliferative disorder is selected from polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM), chronic myelogenous leukemia (CML), myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), juvenile myelomonocytic leukemia (JMML), or systemic mast cell disease (SMCD).